Zoe Diana Draelos, M.D, discusses prebiotic, probiotic and postbiotic skincare products and their role in normalizing the skin microbiome.
Determine whether a laser device is a good investment for a specific practice and, if so, how to choose the right piece of equipment.
Joel Cohen, M.D., shares his response to recent findings regarding the safety of chemical sunscreen and discusses why patients should consider using physical sunscreens.
Dean Celia, our original managing editor, reflects the beginning of Dermatology Times and the medical editors, Dr. Ronald Wheeland and Dr. Norman Levine, who ensured the publication focused on the key industry developments that mattered most to practicing dermatologists.
James Q. Del Rosso, DO, highlights different rosacea treatment options in his session at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.
Drs. Lilit Garibyan, Steve Xu and Kachiu C. Lee highlight a grassroots initiative that encourages physicians to become more involved in innovation in dermatology.
Drs. Lilit Garibyan, Steve Xu and Kachiu C. Lee highlight a grassroots initiative that encourages physicians to become more involved in innovation in dermatology.
Researchers performed a systematic review of available reports on the therapeutic benefit of interleukin (IL)-17/T-helper 17 (Th17) axis inhibitors in patients with generalized pustular psoriasis (GPP). Read what they discovered in this article.
In this month's Innovation article, Steve Xu, M.D., FAAD, highlights a company and innovator who are using artificial intelligence to augment physician decision-making, not replace it.
Drs. López and Kaufman discuss two new studies that examine the use of ultrasound technology as a new modality for treatment of erythematotelangiectatic and refractory rosacea.
Harold J. Brody, MD, provides his best tips and tricks for superficial and medium depth chemical peels in a presentation at the 2022 ASDS Annual Meeting.
How should dermatologists feel about direct-to-consumer online companies compounding prescription formulations? Read from three experts on the topic in this article.
How should dermatologists feel about direct-to-consumer online companies compounding prescription formulations? Read from three experts on the topic in this article.
How should dermatologists feel about direct-to-consumer online companies compounding prescription formulations? Read from three experts on the topic in this article.
Hans Hofland, Ph.D, and Dr. Steve Xu shine a spotlight on Dermira and its novel topical medicine indicated for primary axillary hyperhidrosis in patients 9 years of age and older.
Todd Petersen, CEO of VitalSkin Dermatology, discusses the last part of your transition journey – ensuring a smooth, successful transition for you, your team and your patients.
Carol Soutor, M.D., writes about efficacy and safety of mind-body therapies for the treatment of various skin conditions.
Kim, who received the Marion B. Sulzberger Award at the 2024 American Academy of Dermatology Annual Meeting, discussed itch research an implications for clinical practice.
Nuogen Pharma’s mission is to deliver the first FDA-approved anti-itch medication for chronic pruritus of unknown origin (CPUO) and other chronic itch conditions.
Read one New York physician's insights on practice survival and patient care during the pandemic.
One notable change: CVS Caremark has removed the Humira biosimilar Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
At the inaugural Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed how NPs and PAs can advance their professional growth by seizing opportunities to share their clinical experiences.
Patricia Richey, MD, delves into efficacy of the 1927 and 1550 nanometer lasers to prevent skin cancers.
Take a world tour of the global game-changing advances and home-grown success strategies dermatologists in the United States and abroad are using to tackle the challenges of acne.
Rocco Serrao, MD, FAAD, addresses potential barriers to access and affordability of narrowband UVB phototherapy and topical medications for vitiligo treatment, while highlighting available resources to assist patients in overcoming these obstacles.
Patients with persistently controlled atopic dermatitis who had their doses reduced were able to maintain their low disease activity.
Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.
Chilukuri shared that 2 new sunscreen ingredients, physalis angulata and pycnogenol, can prevent heat-induced pigmentation, offering new options for patients.